Loading
A phase 2 trial of Domvanalimab, Quemliclustat, Zimberelimab in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.
Study With Various Immunotherapy Treatments in Participants With Lung Cancer is a phase 2 interventional study registered as NCT05676931 by Gilead Sciences, with 400 participants planned, started 2023-02-21 and due to reach its primary completion in 2027-12. Interventions recorded: Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Quemliclustat, Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite).
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Small-cell lung cancer.
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite).
Shares Domvanalimab, Gilead Sciences (incl. Kite), Non-small-cell lung cancer.
Shares Domvanalimab, Zimberelimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Quemliclustat, Domvanalimab, Zimberelimab, Non-small-cell lung cancer.
Shares Domvanalimab, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/